Bristol Myers Squibb (NYSE:BMY) Sets New 52-Week High – Here’s Why

Bristol Myers Squibb Company (NYSE:BMY) reached a new 52-week high during trading on Monday . The company traded as high as $63.24 and last traded at $63.07, with a volume of 1250600 shares changing hands. The stock had previously closed at $62.09.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of recent analyst reports. Raymond James Financial restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. Bank of America lowered their price target on Bristol Myers Squibb from $67.00 to $66.00 and set a “buy” rating for the company in a research note on Friday, July 10th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Finally, Weiss Ratings downgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, July 16th. Eight investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $61.25.

Bristol Myers Squibb Trading Up 1.7%

The business has a 50 day simple moving average of $57.70 and a 200-day simple moving average of $58.17. The stock has a market capitalization of $129.97 billion, a price-to-earnings ratio of 17.88, a PEG ratio of 0.18 and a beta of 0.23. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same quarter last year, the firm posted $1.80 earnings per share. Bristol Myers Squibb’s revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.34 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be paid a $0.63 dividend. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.0%. Bristol Myers Squibb’s payout ratio is presently 70.79%.

Institutional Investors Weigh In On Bristol Myers Squibb

Several large investors have recently made changes to their positions in BMY. Swiss RE Ltd. bought a new stake in Bristol Myers Squibb in the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. increased its holdings in Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares in the last quarter. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb during the 2nd quarter worth about $25,000. Bayban acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at about $32,000. Institutional investors own 76.41% of the company’s stock.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.